M Gilson

1.1k total citations
14 papers, 802 citations indexed

About

M Gilson is a scholar working on Physiology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M Gilson has authored 14 papers receiving a total of 802 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Physiology, 8 papers in Surgery and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M Gilson's work include Asthma and respiratory diseases (9 papers), Eosinophilic Esophagitis (8 papers) and Respiratory and Cough-Related Research (5 papers). M Gilson is often cited by papers focused on Asthma and respiratory diseases (9 papers), Eosinophilic Esophagitis (8 papers) and Respiratory and Cough-Related Research (5 papers). M Gilson collaborates with scholars based in United Kingdom, United States and France. M Gilson's co-authors include Robert G. Price, Steven W. Yancey, Héctor Ortega, Richard Leigh, Eric Bradford, Njira Lugogo, Pascal Chanez, Christian Domingo, Frank C. Albers and Wendy C. Moore and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, European Respiratory Journal and Otolaryngology.

In The Last Decade

M Gilson

13 papers receiving 793 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M Gilson United Kingdom	8	659	478	237	179	169	14	802
Yanping Wu United States	7	920 1.4×	628 1.3×	260 1.1×	250 1.4×	275 1.6×	17	999
Luigi Zucchi Italy	11	283 0.4×	234 0.5×	59 0.2×	90 0.5×	73 0.4×	27	374
Patrizia Ruggiero Italy	12	205 0.3×	215 0.4×	57 0.2×	59 0.3×	55 0.3×	22	368
Yoriyuki Murata Japan	10	166 0.3×	228 0.5×	44 0.2×	40 0.2×	35 0.2×	36	333
Inderpal Randhawa United States	10	87 0.1×	119 0.2×	56 0.2×	47 0.3×	26 0.2×	38	287
W. Brett Cherry United States	3	170 0.3×	43 0.1×	420 1.8×	43 0.2×	326 1.9×	3	571
Antonella Fossi Italy	13	139 0.2×	317 0.7×	137 0.6×	8 0.0×	61 0.4×	34	506
Jean Charles Dalphin France	6	107 0.2×	189 0.4×	57 0.2×	30 0.2×	54 0.3×	10	435
R Mikami United States	3	536 0.8×	360 0.8×	95 0.4×	8 0.0×	16 0.1×	6	636
Raphaël Lhote France	11	143 0.2×	122 0.3×	32 0.1×	5 0.0×	53 0.3×	25	372

Countries citing papers authored by M Gilson

Since Specialization

Citations

This map shows the geographic impact of M Gilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Gilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Gilson more than expected).

Fields of papers citing papers by M Gilson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Gilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Gilson. The network helps show where M Gilson may publish in the future.

Co-authorship network of co-authors of M Gilson

This figure shows the co-authorship network connecting the top 25 collaborators of M Gilson. A scholar is included among the top collaborators of M Gilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Gilson. M Gilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Pavord, Ian, Robert Chan, Nicola Brown, et al.. (2024). Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study. Annals of Medicine. 56(1). 2417184–2417184. 11 indexed citations

Moore, Wendy C., Oliver Kornmann, Marc Humbert, et al.. (2021). Stoppingversuscontinuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal. 59(1). 2100396–2100396. 71 indexed citations

Roufosse, Florence, Jean‐Emmanuel Kahn, Marc E. Rothenberg, et al.. (2020). Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 146(6). 1397–1405. 111 indexed citations

Kahn, Jean‐Emmanuel, Gerald J. Gleich, M.E. Rothenberg, et al.. (2020). Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: A Phase III, Randomized, Placebo-Controlled Trial. A4212–A4212.

Khurana, Sandhya, Eric Bradford, M Gilson, et al.. (2020). Long-term safety and durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX. Pneumologie. 1 indexed citations

Bel, EH, Oliver Kornmann, Marc Humbert, et al.. (2020). P211 CLINICIAN/PATIENT PERCEPTION: ASTHMA SEVERITY DECREASES AND RESPONSE INCREASES WITH CONTINUING VERSUS STOPPING LONG-TERM MEPOLIZUMAB (COMET). Annals of Allergy Asthma & Immunology. 125(5). S30–S30. 1 indexed citations

Bel, Elisabeth H., Wendy C. Moore, Oliver Kornmann, et al.. (2020). Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. 5280–5280. 5 indexed citations

Moore, Wendy C., Oliver Kornmann, Marc Humbert, et al.. (2020). Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma: The Randomized Comet Trial. A4211–A4211. 3 indexed citations

Khurana, Sandhya, Guy Brusselle, Elisabeth H. Bel, et al.. (2019). Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clinical Therapeutics. 41(10). 2041–2056.e5. 127 indexed citations

10.

Khatri, Sumita, Wendy C. Moore, Peter G. Gibson, et al.. (2018). Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology. 143(5). 1742–1751.e7. 219 indexed citations

11.

Lugogo, Njira, Christian Domingo, Pascal Chanez, et al.. (2016). Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clinical Therapeutics. 38(9). 2058–2070.e1. 219 indexed citations

12.

Albers, Frank C., Njira Lugogo, M Gilson, Robert G. Price, & Steven W. Yancey. (2016). Long-Term Safety and Efficacy of Mepolizumab in Patients with Severe Eosinophilic Asthma. Journal of Allergy and Clinical Immunology. 137(2). AB14–AB14. 3 indexed citations

13.

Carballido, Joaquı́n, R. Fourcade, Arcangelo Pagliarulo, et al.. (2011). Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial. International Journal of Clinical Practice. 65(9). 989–996. 17 indexed citations

14.

Ferguson, Berrylin J., et al.. (2002). Short Treatment Durations for Acute Bacterial Rhinosinusitis: Five Days of Gemifloxacin versus 7 Days of Gemifloxacin. Otolaryngology. 127(1). 1–6. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact